VT-CANNATROL
11.7.2024 14:04:28 CEST | Business Wire | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today an exclusive partnership with Paralab Green, Europe’s premier distributor of cannabis processing solutions, establishing distribution of the company’s patented Vaportrol® Technology throughout Europe.
“This partnership truly represents the best of cannabis processing,” said Jane Sandelman, CEO and Co-Founder of Cannatrol. “Paralab Green has established relationships within the European cannabis industry and has a unique understanding of the rapidly growing market. We look forward to opening international access to Cannatrol’s science-backed technology that will benefit cultivators—and ultimately consumers.”
Paralab Green supplies over 70% of licensed production facilities throughout the European Union, offering a range of instrumentation for the cannabis industry, from production to quality control.
“The European market continues to lead the way in Good Manufacturing Practices (GMP) compliance, and this partnership with Cannatrol is a pivotal addition that enhances our portfolio at Paralab Green,” said Rui Soares, CEO of Paralab Green. “The Cannatrol team brings invaluable scientific expertise to optimize and simplify the drying and curing process. This collaboration reinforces our commitment to excellence, raising industry standards and delivering exceptional value to our customers.”
Cannatrol systems ensure consistent water activity and vapor pressure, delivering elevated product quality, increased yields, GMP regulatory compliance and bottom-line improvements. Cannatrol’s patented postharvest technology is proven to increase curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition.
In addition to Europe, Paralab Green operates in Israel, North Africa and Latin America—opening the door for operators in those regions to access Cannatrol technology.
To learn more about Cannatrol’s Vaportrol® Technology, visit cannatrols.com.
About Cannatrol
Cannatrol supports commercial cannabis cultivation by streamlining and tightly controlling the critical drying, curing processes as well as postharvest storage. With patented Vaportrol® Technology, the system controls water loss by regulating the vapor pressure and ensures the correct final water activity, critical for terpene preservation, maximized potency, increased yield and premium quality. Cannatrol’s environmental control solution ensures consistent results for every climate and geography, taking the guesswork and risk out of seasonal humidity and temperature swings. Learn more at cannatrols.com.
About Paralab Green
Paralab Green, a division of Paralab with 32 years of industry leadership, specializes in providing innovative equipment solutions tailored for the cannabis industry. With a background in serving the pharmaceutical, biotechnology, energy, and chemical sectors, Paralab Green brings extensive expertise to cannabis cultivation, extraction, and production. Operating from offices in Portugal and Spain, we are the trusted solution provider for the majority of licensed producers in Europe. Paralab Green combines technical prowess with exceptional customer support to drive innovation and set new standards in the cannabis sector. Learn more at paralab-green.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711844879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom